Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus DURAGESIC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus DURAGESIC 75.
DALGAN vs DURAGESIC-75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic